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Abstract
Summary The purpose of this study was to evaluate the mea-
surement properties of the Osteoporosis Assessment
Questionnaire-Physical Functioning (OPAQ-PF). Based on
this study, the OPAQ-PF has confirmed unidimensionality
and acceptable reliability, construct validity, and sensitivity
to change in a recent fracture/no recent fracture osteoporosis
sample.
Methods Dimensionality was established through exploratory
and confirmatory factor analysis. Patients completed three
patient reported outcome (PRO) measures and four
performance-based measures (PBMs) at baseline to enable
an evaluation of construct validity. Patients without a recent
fracture completed the OPAQ-PF 2 weeks after baseline to
enable an evaluation of test–retest reliability. Ability to detect
change and interpretation of change were investigated follow-
ing completion of the OPAQ-PF 12 and 24weeks postbaseline
by patients with a recent fracture.
Results A prospective psychometric validation study in 144
postmenopausal women, withmoderate to severe osteoporosis,
37 of whom had experienced a recent fragility fracture
(<6 weeks). Unidimensionality was established for the
OPAQ-PF by factor analysis. The OPAQ-PF had good internal
consistency (α=0.974) and test–retest reliability (mean
intraclass correlation coefficient (ICC) 0.993. The OPAQ-PF
differentiated between patients with/without recent fracture,
and by severity of osteoarthritis; it correlated strongly with
hypothesized-related scales and PBMs (r>0.3, p<0.001).
Ability to detect change was established with high correlations
between changes in OPAQ-PF score and changes in global
concept scores in recent fracture patients (r≥0.6, 24-week
change). Effect size of change on OPAQ-PF score increased
by level of global change (p<0.001). Anchor-based methods
identified an OPAQ-PF change of 10 at an individual patient
level and 20 at a group level as meaningful to patients.
Conclusions The OPAQ-PF has confirmed unidimensionality
and acceptable reliability, construct validity, and sensitivity to
change in a recent fracture/no recent fracture osteoporosis
sample.
Keywords OPAQ-PF . Osteoporosis . Outcomes
assessment . Patient reported outcomes . Physical function .
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Introduction
Commonly identified consequences associated with
osteoporotic-related fractures are impaired physical function-
ing, disability, depression, social isolation, pain, and loss of
independence. These impacts of osteoporosis on a patient’s
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life are often measured in clinical trials using patient-reported
outcome (PRO) instruments assessing overall health-related
quality of life (HRQL) [1-3]. However, specific aspects of
HRQL need to be well measured in the development of new
health technologies as a means to demonstrate and meet
patient expectations to maintain and live an active, healthy
life with the ability to independently perform activities of
daily living, even after experiencing a fracture event [4].
New treatments in development for osteoporosis are sub-
ject to regulatory review of demonstrated effectiveness and
safety, evaluated using measures and methods that conform to
published regulatory guidance. The US Food and Drug
Administration (FDA) requires evidence of a specific treat-
ment benefit, defined as a favorable effect on a meaningful
aspect of how a patient feels, functions, or survives [5].
Meaningful capture of how a patient feels (a patient’s physical
sensation or perceived mental state related to health within
typical “daily” life, e.g., pain, low mood) or functions
(a patient’s ability to perform an activity that is a meaningful
part of a typical “daily” life) relies on direct report from the
patient, known as a PRO [5].
A number of measures are available to assess health-related
outcomes in osteoporosis that are reported from the patient
perspective. Generic measures most commonly used to eval-
uate patient-reported aspects of HRQL include the Short Form
36 (SF-36 and the EQ-5D [6-12]. Disease-targeted measures
have also been developed and include, but not limited to, the
Osteoporosis Assessment Questionnaire (OPAQ) [13], the
Osteoporosis Quality of Life Questionnaire (OQLQ)
[14, 15], the Osteoporosis Functional Disability Questionnaire
(OFDQ) [16], the Osteoporosis-Targeted Quality of Life
Questionnaire (OPTQOL), the Quality of Life Questionnaire
of the European Foundation for Osteoporosis (QUALEFFO)
[17, 18], and the Questionnaire Quality of Life in Osteoporosis
(QUALIOST) [19].
The FDA’s definition of what constitutes PRO evidence of
specific treatment benefit requires instruments with a concep-
tual focus on feelings or function suggests measurement of
proximal concepts (e.g., symptoms) rather than distal concepts
(e.g., HRQL) to be most appropriate. The Osteoporosis
Assessment Questionnaire-Physical Functioning (OPAQ-PF)
has been developed specifically to meet the requirements of
evaluating osteoporosis treatment effectiveness [20]. This new
15-item measure captures impact of osteoporosis on patients
ability to perform daily activities of physical function and was
previously adapted from theOPAQ v 2.0 [13] through a process
of item reduction based on item response theory, input from key
thought leaders on quality of life issues and measurement in
osteoporosis, concept elicitation, and cognitive debriefing in-
terviews conducted with osteoporotic patients with and without
experience of fracture [20]. The aim of this current study was to
evaluate the measurement properties of the OPAQ-PF follow-
ing published psychometric standards [21-23].
Methods
Design
This prospective, clinical site-based psychometric validation
study was designed to confirm the conceptual framework of
the OPAQ-PF (using factor analysis) and evaluate the follow-
ing measurement properties of the instrument: reliability
(internal consistency, item homogeneity, test–retest); construct
validity (known groups and convergent validity); ability to
detect change; and interpretation of change.
Patients completed the OPAQ-PF and other measures at
baseline and then either 2 weeks later (no recent fracture
group) or at 12 and 24 weeks (recent fracture group). All
psychometric properties were evaluated on baseline data apart
from test–retest reliability which was evaluated using data
collected at 2 weeks, ability to detect change, and interpreta-
tion of changewhich used data collected at 12 and 24weeks in
the recent fracture group.
The study protocol and materials were developed with
input from two expert clinicians (DTG and SS). Institutional
review board (IRB) approval was obtained for the study
(Protocol OXO2550; original approval from Independent
Investigational Review Board, 21 October 2011).
Sample
The study aimed to recruit approximately 150 participants in
total: 100 osteoporosis patients without recent fracture, and 50
recent osteoporotic fracture patients. This would enable 80 %
power to be achieved to detect differences (at two-sided
p<0.05) to a moderate effect of around 0.5. Participants were
recruited through ten clinical sites distributed across eight US
states; most were specialist orthopedic sites, generally based
within physician-led practices which varied in size.
Eligibility criteria were developed in consultation with the
two key thought leaders. All participants were:
(1) Postmenopausal women (aged ≥50 years of age,
reporting no menstruation in previous 12 months).
(2) Diagnosed withmoderate to severe osteoporosis (T-score
of≤−2.5) or a history of a nontraumatic or fragility
clinical fracture (symptomatic and diagnosed by X-ray).
Participants were classified into one of two subgroups:
those with or without recent osteoporotic fracture.
Participants without fracture were expected to experience
stability in their ability to perform daily activities of physical
functioning for evaluation of test–retest reliability of the
OPAQ-PF. Participants with recent osteoporotic fracture
(within 6 weeks prior to baseline, fracture date taken as the
date of diagnostic X-ray) were expected to experience change
in their ability to perform daily activities of physical
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functioning over 12-24 weeks for evaluation of the OPAQ-
PF’s ability to detect change.
Participants without a recent fracture had to be able to
ambulate independently (with or without a walking aid).
Participants with a recent fracture had to have been able to
ambulate independently prior to the fracture and to be able to
ambulate with or without a walking aid at their baseline visit.
Patients with Parkinson’s disease and/or other neuromuscular
disorders were excluded. Patients who had received proce-
dures potentially impacting physical functioning were also
excluded (vertebroplasty and/or kyphoplasty).
Recruitment of the recent fracture group aimed for a bal-
ance of upper body (e.g., wrist, shoulder, and upper arm),
lower body (e.g., hip, tibia, ankle, and foot), and trunk fracture
(e.g., rib, and vertebral). Types of fracture considered difficult
to classify as fragility, versus traumatic, not to result in suffi-
cient physical impairment for OPAQ-PF validation purposes,
or to have unpredictable healing rates were excluded.
Examples of excluded fracture types were toe, finger, clavicle,
pelvis, or face fracture.
Measures
The OPAQ-PF was previously adapted from the OPAQ v2.0
and was designed to evaluate participant’s ability to perform
their daily activities of physical function during the past 7 days
covering mobility (five items), physical positions (six items)
and transfers (four items) [20]. Items are rated on a six-point
Likert response scale ranging from no difficulty to completely
avoided doing this. All 15 items are summed and normalized
to a 0–100 scale to provide a total score, where 0 indicates the
worst health status and 100 no difficulties.
Three additional PROs were included to evaluate the con-
struct validity of the OPAQ-PF: The Western Ontario and
McMaster Universities Arthritis Index (WOMAC), the SF-
36, and QUALEFFO-41. The WOMAC [24] was designed to
assess pain, disability, and joint stiffness in osteoarthritis
during the last 48 hours. The SF-36 [25] was designed to
measure health status in a wide range of conditions as well
as in the general population. Eight SF-36 domain scores
provide a health profile (bodily pain, general health percep-
tions, mental health, physical functioning, role limitations due
to emotional problems, role limitations due to physical prob-
lems, social functioning, and vitality), as well as two compo-
nent summary scores for physical (PCS) and mental health
(MCS). The QUALEFFO-41 [26, 27] was designed to mea-
sure HRQL in patients with vertebral fractures and produces
five domain scores (pain, physical function, social function,
general health perception, mental function) and a total score.
Three global concept items were developed to evaluate the
ability of the OPAQ-PF to detect change and to evaluate
interpretation of change [28]. Global concept items were
self-completed by participants to reflect overall difficulty in
the last 7 days with mobility, physical positions, and transfer
activities due to osteoporosis. Participants rated difficulty on a
five-point scale ranging from “no difficulty” (0) to “severe
difficulty” (5).
Four performance-based measures (PBMs) were included
in the study to help evaluate the construct validity of the
OPAQ-PF: ten-meter walk test (10MWT); timed up and go
(TUG); functional reach (FR), and timed unsupported steady
stand (TUSS). 10MWT is a measure of gait speed; the indi-
vidual walks for 10 mwithout assistance (other than with their
usual walking aid) at their usual pace. TUG is a test of balance
and mobility; the participant is asked to stand up from a chair
and walk a distance of 3 m at their normal pace, turn around,
walk back to the chair and sit down again, using their usual
walking aid. For 10MWTand TUG, longer times to complete
tests reflect worse health status. FR is a test of balance im-
pairment and change in balance performance: the maximal
forward reach by the participant is measured, using a fixed
base of support. Distance is recorded in centimeters, with a
shorter reach reflecting a worse health status. TUSS is test of
balance impairment associated with an increased risk for
falling [29]. The participant is asked to stand holding onto a
support (e.g., a table or chair), then put their hands by their
sides and stand as long as they feel safe and steady (a maxi-
mum of 60 s), putting their hands back on the support if they
feel unsteady, at which point timing stops. Shorter times
reflect poorer balance and risk of falling. The PBMs were
completed by participants under the supervision of site staff.
Each test was repeated three times with the score being the
average of the three attempts.
Procedures
Site staff received in-person training to ensure familiarity with
protocol requirements, study procedures, and materials.
Clinical site staff screened for eligibility using chart review
and discussion with individual patients.
Baseline visit
All participants (with and without recent fracture) attended
the clinical site for a baseline visit. Participants completed
all PROs and PBMs and provided sociodemographic and
other background information. Site staff completed a med-
ical history form at the baseline visit recording details of
bone mass density, previous fractures, current medication,
and comorbidities.
Week 2 visit
Participants without a recent fracture completed the OPAQ-PF
and global concept items 2 weeks (median 14 days, IQR 14 to
17 days) after baseline.
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Weeks 12 and 24 visits
Participants with a recent fracture attended visits at 12-week
(median 12.0 weeks, IQR 12.0 to 12.8 weeks) and 24-week
(median 24.1 weeks, IQR 24.0 to 24.9 weeks) postbaseline
and completed the OPAQ-PF and global concept items.
Statistical analysis
Scale structure and conceptual framework of the OPAQ-PF
To investigate whether the three aspects of daily activities of
physical functioning measured by the OPAQ-PF are related,
the scale structure was evaluated by both Exploratory and
Confirmatory Factor Analysis (EFA and CFA, respectively),
as CFA commonly requires a minimum sample size of 200
[30]. For the EFA, SAS PROC FACTOR was used with
maximum likelihood extraction. The CFA was performed by
fitting structural equation models using SAS PROC TCALIS,
utilizing a range of measures of fit to compare two competing
models: either a one general factor or a three-factor structure.
Distribution of scores
OPAQ-PF item and score variability (frequency and percent-
age of endorsement) was assessed to evaluate score distribu-
tions, floor, and ceiling effects.
Reliability
The internal consistency of the OPAQ-PF was evaluated with
baseline data using Cronbach’s alpha [31] for the total sample
and each subgroup. Individual item scores were correlated
with the OPAQ-PF total score further to assess the homoge-
neity of the items (item-total correlation). Test–retest reliabil-
ity (intraclass correlation coefficient, ICC) of the OAPQ-PF
score was assessed using baseline and week 2 follow-up data
from patients with no recent fracture and reporting no change
on each of three global concept items between baseline and
week 2.
Construct validity (known groups)
Known-groups analysis was conducted on baseline data. It
was hypothesized that patients who have had a recent fracture,
had osteoarthritis, or had high WOMAC scores (0 indicates
better WOMAC health status) would have poorer OPAQ-PF
scores than comparator groups. In addition, patients in the no-
recent-fracture group but who had experienced fractures at
some point previously were expected to have poorer OPAQ-
PF scores if fracture was experienced more recently than
patients experiencing fractures longer ago (split at the medi-
an). Comparisons were also made by fracture location.
Significant group differences were tested using Mann–
WhitneyU tests or independent sample t tests and effect sizes.
Construct validity (convergent validity)
Analysis of convergent validity was conducted on baseline
data with calculation of Spearman’s correlation coefficients
(rs). The OPAQ-PF was expected to correlate positively with
the SF-36 physical functioning, role functioning, bodily pain,
vitality, and PCS domain scores. No relationships were ex-
pected between the OPAQ-PF and the remaining SF-36 do-
mains. Negative correlations were hypothesized between the
OPAQ-PF and (i) the WOMAC total and domain scores and
(ii) the QUALEFFO-41 pain, physical function, and total
scores, in line with their reversed scoring schemes. No rela-
tionships were expected between the OPAQ-PF and the social
function, general health perception, and mental function
QUALEFFO-41 domains. The 10MWT and the TUG were
expected to correlate negatively with the OPAQ-PF, in line
with the revered scoring schemes. The FR and TUSS were
both expected to correlate positively with the OPAQ-PF. The
existence of observed relationships with a correlation coeffi-
cient≥0.3 and greater than correlations, where no relationship
was hypothesized, were taken to support the convergent va-
lidity of the OPAQ-PF. Observed relationships<0.3 and
smaller than correlations, where relationships were expected,
were taken to support divergent validity.
Ability to detect change
The ability of the OPAQ-PF to detect change (at weeks 12 and
24) was assessed by relating the changes in OPAQ-PF to
changes in the perceived global concept scores (mobility,
physical positions, and transfers) in the recent fracture sub-
group. First, the changes in OPAQ-PF scores and global
concept scores at each follow-up point were calculated and
Spearman’s correlation coefficients used to assess their degree
of association. Second, patients were then classified into
change categories based on changes in the global concept
items. Finally, the patterns of mean change, and the associated
effect sizes, in OPAQ-PF score by global change category
were then evaluated. Differences between patient change cat-
egories were tested using parametric and nonparametric anal-
ysis of variances with tests for linear trend.
Interpretation of change
The level of change in OPAQ-PF scores likely to represent
meaningful change to patients at the group level was investi-
gated using both distribution (one standard error of measure-
ment (1SEM) [32]; MDC90) and anchor-based approaches
(mean change score in OPAQ-PF from participants reporting
one unit improvement on a patient-reported global concept
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item). Individual level change, receiver operator characteristic
(ROC) curves were used to identify the OPAQ-PF change
score (the best cut point), which best distinguishes patients
who change to a minimal extent from those who do not. The
area under the curve (AUC) indicates the overall usefulness of
the prediction (the observed AUC is compared with the AUC
of 0.5 expected from a “useless” test), and the best cut point is
identified as the value which maximizes the values of sensi-
tivity (proportion of true “positives” detected) and specificity
(proportion of true “negatives” detected) [33, 34].
Results
In total, 144 osteoporosis participants were recruited into this
study: 107 without recent fracture and 37 with recent fracture.
Recruitment numbers varied between the sites; mean 14.4
(range 2–37).
Patient demographics and clinical characteristics
Homogeneity between the two study groups was confirmed
for most demographic/medical history characteristics but with
expected differences in terms of time since most recent fracture
(more recent for recent fracture group), pain medication (more
use for recent fracture group), and use of bisphosphonates
(more use for recent fracture group; Table 1). The majority of
the sample reported taking some sort of pharmaceutical agent
for their OP (n=117, 81.3 %). For the combined sample, mean
age at diagnosis was 62.8 years (SD 7.08, range 43.4 to
84.0 years). Fracture location for the recent fracture group
was well distributed: upper body n=15 (40.5 %), lower body
n=10 (27.0 %), trunk n=12 (32.4 %), and the most commonly
reported comorbid conditions were hypertension (n=68,
47.2 %), high cholesterol (n=55, 38.2 %), osteoarthritis
(n=53, 36.8 %), depression/anxiety (n=39, 27.1 %), and eye
conditions (n=36, 25.0 %).
Scale structure and conceptual framework of the OPAQ-PF
EFA maximum likelihood extraction identified one factor
with an eigenvalue>1, with 75 % of the variability being
explained by this one factor onwhich all items loaded strongly
(>0.74). CFA found a significant deterioration in model fit
when fitting three (uncorrelated) factors compared with the
one factor model (overall χ2 fit statistics=644.74 vs. 764.00,
p<0.0001; χ2/df ratios 7.16 vs. 8.49).
Distribution of scores
Mean OPAQ-PF scores were 75.7 (SD 24.9, range 5.33–100),
with 22 % achieving the maximum score (Table 2).
Participants with recent fracture reported greater impairment
on the OPAQ-PF than those with no recent fracture (mean
score 57.0 vs. 82.2, p<0.001), with 2.7 % achieving the
maximum score compared with 29.0 % of the no recent
fracture group. Greater variability in scores was found in the
recent fracture group. A similar pattern was identified at the




Good internal consistency was demonstrated with a
Cronbach’s alpha value of 0.974 for the entire sample; similar
values were reported for the no recent fracture group
(α=0.974) and the recent fracture group (α=0.961) (Table 3).
Item homogeneity
Item-total correlations ranged from 0.733 to 0.923 (Table 3).
Test–retest reliability
Good test–retest reliability was demonstrated for the OPAQ-
PF score with a mean ICC of 0.933 (95 % CI 0.87 to 0.97)




OPAQ-PFwas able to discriminate well between the no recent
fracture and recent fracture groups (mean 82.19 SD 21.08 vs.
57.05 SD 26.09, p<0.001), and between patients defined by
severity of osteoarthritis (WOMAC≥40 vs. <40: mean 90.2
SD 12.6 vs. 53.3 SD 21.3, respectively, p<0.001). The
OPAQ-PF was notable to discriminate between participants
in terms of whether or not they had osteoarthritis, time since
last fracture for fractures experienced >6 weeks from baseline,
and for the recent fracture participants, between fracture loca-
tion (upper body, lower body, and trunk).
Convergent validity
As hypothesized, the OPAQ-PFwas positively correlated with
the SF-36 physical functioning, role functioning, bodily pain,
vitality, and PCS domain scores. While the OPAQ-PF also
correlated with the remaining SF-36 domains where no rela-
tionship had been expected, correlations were consistently
higher with the physical domains and the PCS (rs=0.69) than
with the mental domains and the MCS (rs=0.38). The OPAQ-
PF was negatively correlated with the WOMAC total score
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and all WOMAC domain scores. While large and negative
correlations were observed as hypothesized between the
OPAQ-PF and the QUALEFFO-41 pain, physical function,
and total scores, large correlations were also observed with the
social function, general health perception, and mental function
QUALEFFO-41 domains. As hypothesized, the OPAQ-PF
correlated negatively with the 10MWT and the TUG. All
reported relationships were significant at p<0.001 with corre-
lations≥0.3.
Ability to detect change
The global concept scores indicated that a large propor-
tion of recent fracture patients were either unchanged or
improved at weeks 12 and 24. At 24 weeks, 34 % report-
ed no change in mobility, 28 % in physical positions, and
52 % in transfers, while 59 % reported improvement in
mobility, 59 % in physical positions, and 47 % in
transfers.
Table 1 Participant characteristics
n (percent) No recent fracture (n=107) Recent fracturea (n=37) Total (n=144)
Age, years, mean (SD) [min–max, years] 69.7 (8.70) [52.0–88.8] 69.4 (9.70) [51.3–87.9] 69.6 (8.93) [51.3–88.8]
Education
High school or less 36 (33.7 %) 15 (40.5 %) 51 (35.5 %)
Some college 33 (30.8 %) 12 (32.4 %) 45 (31.3 %)
College degree 25 (23.4 %) 4 (10.8 %) 29 (20.1 %)
Graduate degree 13 (12.1 %) 6 (16.2 %) 19 (13.2 %)
Ethnicity
Asian 2 (1.9 %) 0 (0 %) 2 (1.4 %)
Black 1 (0.9 %) 3 (8.1 %) 4 (2.8 %)
Hispanic 4 (3.7 %) 2 (5.4 %) 6 (4.2 %)
White or Caucasian 100 (93.5 %) 32 (86.5 %) 132 (91.7 %)
Employment
Employed (part or full time) 22 (20.6 %) 6 (16.2 %) 28 (19.5 %)
Retired 64 (59.8 %) 21 (56.8 %) 85 (59.0 %)
Looking after home/family 11 (10.3 %) 2 (5.4 %) 13 (9.0 %)
Not working/not retired 10 (9.3 %) 8 (21.6 %) 18(12.5 %)
Disease duration [min–max, years] 6.83 (4.80), n=94 [0.45–19.8] 8.02 (6.75), n=25 [0–30.6] 7.08 (5.26), n=119 [0–30.6]
Time (months) since most recent fracture
[min–max, months]
123.9 (193.5), n=53 [1.97–703.8] 0.75 (0.41), n=37 [0–1.35] 73.3 (160.0), n=90 [0–703.8]
Medication
Calcium 69 (64.5 %) 24 (64.9 %) 93 (64.6 %)
Vitamin D 73 (68.2 %) 24 (64.9 %) 97 (67.4 %)
Bisphosphonates 68 (63.6 %) 12 (32.4 %) 80 (55.6 %)
Other 29 (27.1 %) 9 (24.3 %) 38 (26.4 %)
Pain medicationsb 64 (59.8 %) 28 (75.7 %) 92 (63.9 %)
Fracture location
Shoulder/humerus – 4 (10.8 %)
Radius/wrist – 9 (24.4 %)
Ulna and radius – 2 (5.4 %)
Ribs – 6 (16.2 %)
Vertebra – 6 (16.2 %)
Hip/femoral neck – 3 (8.1 %)
Ankle/malleolus – 4 (10.8 %)
Foot – 3 (8.1 %)
a Recent fracture was defined as a nontraumatic or fragility clinical fracture (symptomatic and diagnosed by X-ray) in the 6 weeks prior to baseline.
Fracture date taken as the date of diagnostic X-ray
b Includes eight patients who reported taking pain medications their clinicians were unaware of and five patients who did not report taking medications
prescribed by their clinicians
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Large correlations were observed between changes in
OPAQ-PF score and changes in global concept scores.
Strong, statistically significant associations were observed at
12 weeks, and even greater associations at 24 weeks: transfers
rs=0.50 at 12 weeks and rs=0.65 at 24 weeks, mobility
rs=0.46 at 12 weeks and rs=0.60 at 24 weeks, and physical
positions rs=0.75 at 12 weeks and rs=0.73 at 24 weeks. The
amount of change in OPAQ-PF scores and the associated effect
sizes generally increased with perceived degree of change
(improvement), observed associations were strong, and the
tests for linear trend were statistically significant (all p<0.01).
Interpretation of change
Distribution-based approaches identified a value of 4.0 for
interpreting a minimum change on the OPAQ-PF based on
the SEM approach, and anMDC90 of 9.6 (Table 3). This is the
smallest value that could be used to indicate minimal change
on an individual patient basis. The anchor-based approaches
Table 2 OPAQ-PF
summary statistics




Mean (SD) 75.7 (24.9)
Median (IQR) 83.3 (58.0–98.7)
Min, max 5.33, 100
n (percent) max 32 (22.2 %)
No recent fracture (n=107)
Mean (SD) 82.2 (21.1)
Median (IQR) 92.0 (69.3–100)
Min, max 28, 100
n (percent) max 31 (29.0 %)
Recent fracture (n=37)
Mean (SD) 57.0 (26.1)
Median (IQR) 58.7 (38.7–78.7)
Min, max 5.33, 100
n (percent) max 1 (2.7 %)
Table 3 OPAQ-PF reliability: item-total correlations and internal consistency
OPAQ-PF item, item-total correlationa Overall (n=144) No fracture (n=107) Fracture (n=37)
1. Walking to do your daily chores or errands (e.g., grocery shopping, taking out
garbage, house work, going to post office, walking the dog)
0.923 0.927 0.863
2. Walking unaided so you can do your day to day activities 0.797 0.808 0.718
3. Carrying objects in order to perform your day to day activities
(e.g., a bag of groceries, a bag of garbage)
0.870 0.843 0.829
4. Walking one block 0.860 0.867 0.747
5. Climbing one flight of stairs or steps 0.863 0.867 0.785
6. Bending or stooping to do your daily chores or errands (e.g., grocery shopping,
taking out the garbage, housework, going to post office, walking the dog)
0.906 0.887 0.876
7. Lifting objects in order to perform your day to day activities (e.g., a bag of
groceries, a bag of garbage)
0.877 0.868 0.815
8. Reaching overhead in order to perform your day to day activities 0.827 0.871 0.689
9. Picking things up from the floor 0.842 0.846 0.782
10. Standing as much as you needed in order to perform your day to day activities 0.863 0.877 0.807
11. Sitting as much as you needed in order to perform your day to day activities 0.733 0.753 0.716
12. Getting in or out of bed 0.761 0.830 0.580
13. Getting in or out of a chair 0.852 0.830 0.841
14. Getting on or off the toilet 0.857 0.839 0.817
15. Getting in or out of cars on your own 0.844 0.800 0.832
Cronbach’s alphab 0.974 0.974 0.961
SD 24.95 21.08 26.09
SEMc 4.02 3.40 4.21
MDC90
d 9.55 8.08 10.00
a Items should have a significant correlation≥0.30 [36]
b A minimum value of 0.80 is a guideline for demonstrating internal consistency [35], and alpha scores in excess of 0.90 may indicate an overly
homogenous scale, where items may be redundant due to excessive similarity [37]
c Standard error of measurement, SEM=SD×sqrt(1−Cronbach’s alpha)
dMinimal detectable change 90, MDC90=1.68×SEM×sqrt(2)
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described above indicated that, for interpretation at a group
level, the mean OPAQ-PF scores for patients reporting at
least one point of change on the mobility, physical posi-
tions, and transfers global concept items were 19.0, 14.3,
and 13.3, respectively (overall mean 15.5) at 12 weeks and
23.3, 19.2, and 23.6 (overall mean 22.0) at 24 weeks:
overall mean over 12 and 24 weeks=18.8 (~20). The
ROC analyses demonstrated that the OPAQ-PF change
values that can be used to identify minimal change at an
individual level on the mobility, physical positions, and
transfers global concept items are 4.0, 10.0, and 12.7,
respectively (overall mean 8.89) at 12 weeks and 9.3, 9.3,
and 16.0, respectively (overall mean 11.6) at 24 weeks:
mean of overall means at 12 and 24 weeks=10.25 (~10).
Discussion
This study sought to evaluate the psychometric measurement
properties of the OPAQ-PF, a PRO instrument developed with
patients with osteoporosis and designed to assess a patients’
ability to perform daily activities of physical function for
evaluating osteoporosis treatment effectiveness. The study
design allowed for a comprehensive assessment of the psy-
chometric properties of the OPAQ-PF in line with current
FDA regulatory guidelines [5].
The conceptual focus of the OPAQ-PF is a unidimensional
measure of daily activity of physical function; the EFA strong-
ly indicated that the variability in the data was best explained
by one underlying construct and that this single factor alone
was sufficient to explain the majority of the variance in the
data (75 % on principal component extraction). This was
supported by the CFA, i.e., the OPAQ-PF is most appropri-
ately scored in terms of a total score, and the OPAQ-PF
conceptual framework is confirmed.
The OPAQ-PF had a good distribution of scores for pa-
tients with a recent fracture (within 6 months) with scores
ranging across almost the entire spectrum of the 0–100 scale,
and a median score of 58.7. The OPAQ-PF therefore has good
capacity to measure change (improvement or decline) in daily
activities of physical function of osteoporosis patients who
have experienced a recent fracture. However, the OPAQ-PF
did demonstrate a possible ceiling effect for those with no
recent fracture, with 29.0 % scoring the maximum, with a
narrower scoring range (28–100). The OPAQ-PFmay bemost
suitable for measuring the maintenance of the ability to per-
form daily activities of physical function.
The OPAQ-PF demonstrates excellent internal consistency
(α=0.974). A minimum value of 0.80 is a guideline for
demonstrating internal consistency [35]. Alpha scores in ex-
cess of 0.90 may indicate an overly homogenous scale, where
items may be redundant due to excessive similarity [36]. Items
were not deleted as it was felt that they represent clinical
relevant concepts that should be measured as part of the
overall construct. The OPAQ-PF has good stability over a 2-
week period among no recent fracture participants who re-
ported experiencing no change in the previous 7 days, with an
ICC of 0.93Guidelines suggest an ICC>0.70 [35] or 0.90 [22]
as minimum requirements, both of which are exceeded by the
OPAQ-PF.
In terms of construct validity, the OPAQ-PF was able to
differentiate between patients with no recent fracture
(>6 weeks) and patients with a recent fracture (<6 weeks)
and severity of osteoarthritis. The inability of the OPAQ-PF
to discriminate between other identified known groups does
not necessarily reflect poor construct validity. It could be that
the location of fracture and time since fracture>6 weeks (the
no fracture group on average having their most recent fracture
4 years ago) has no bearing on physical activities of daily
living. The small sample sizes for each identified known
group may also explain why no significant differences were
observed.
Convergent validity was evaluated by exploring the rela-
tionship of the OPAQ-PF with three PRO instruments: the
WOMAC, SF-36, QUALEFFO-41, and PBMs. As hypothe-
sized, scores on the OPAQ-PF were most strongly correlated
with physical dimensions of the WOMAC, the physical di-
mensions of the SF-36, and the physical function domain of
the QUALEFFO-41, with lower correlations being observed
with the mental dimensions of the SF-36. The size of the
correlations observed in the relationships between the
OPAQ-PF and the PBMs (specifically, the 10MWT and
TUG) indicate a good level of convergent validity for the
OPAQ-PF.
Results demonstrated that where an osteoporosis patient
has experienced change in their health status related to ability
to perform daily activities of physical function (specifically
mobility, transfers, and physical positions), the OPAQ-PF
captures that change. In patients with a recent fracture, high
correlations were observed between changes in OPAQ-PF
score and changes in patient-reported global concept scores.
Strong statistically significant associations were observed at
12 weeks postbaseline with even greater associations at the
24-week follow-up. The reported effect size statistics at 12
and 24 weeks clearly demonstrate that the greater the degree
of improvement reflected by the change categories, the greater
and more positive the effect sizes for change in the OPAQ-PF
score.
Analysis was undertaken to enable OPAQ-PF change
scores to be interpreted using two established approaches:
distribution and anchor-based. The 1SEM distribution-based
approach identified an OPAQ-PF change score of 4.0 (1SEM)
as being the minimum needed for the change to be meaning-
ful, with a 90 % confidence interval (MDC90) of 9.6.
Distribution-based approaches are useful supporting informa-
tion for interpretation of PRO change scores, as the change
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scores need to be at least as large as a distribution-based value
to rule out the possibility of change in score by chance.
However, values generated by distribution-based approaches
do not necessarily indicate clinically relevant change or
change of a magnitude that is meaningful to patients.
Greater credibility is placed in the anchor-based approaches
[28], which in this analysis compared a one-point change on
global concept items to corresponding score changes on the
OPAQ-PF. The overall mean of the mean changes in OPAQ-
PF score across the three global concept items suggests that, at
a group level, a change in OPAQ-PF score of ~20 points needs
to be achieved before the change can be considered meaning-
ful to patients. At an individual patient level, a change in
OPAQ-PF score of ten points appears meaningful.
This study had several limitations. Recruitment of the
recent fracture subgroup fell short of the target sample size
of 50. The power of the study was therefore less than planned.
While this may partially account for the inability of the
OPAQ-PF to differentiate between certain groups, e.g.,
with/without osteoarthritis and fracture location, the observed
differences between these groups were small and other statis-
tically significant group differences were identified. Thus
while the demonstration of the ability of the OPAQ-PF to
detect change was limited to the relatively small “recent
fracture” group, strong and highly statistically significant
associations were observed between changes in the OPAQ-
PF and changes in perceived degree of improvement, indicat-
ing meaningful results despite the small sample. Another
limitation is that study design for the change analysis focused
on improvements. Further work is needed to verify the ability
of the OPAQ-PF to capture decline in osteoporosis patients, as
well as to gather further evidence for the ability to capture
improvements on a larger sample. In addition, for interpreta-
tion of change, the change in global concept scores was
framed in terms of hypothesized domains which were not
verified in the factor analysis. Nevertheless, effect sizes of
change within categories of perceived change (with approxi-
mately one third of patients reporting a minimal degree of
improvement) showed clear highly statistically significant
group heterogeneity and linear trends; further work is planned
to confirm interpretation of change scores based on a global
concept item for daily activities of physical function which
will be more closely aligned to the unidimensional structure
confirmed for the OPAQ-PF. The study may not be general-
izable to all osteoporosis patients, and so the validity of the
OPAQ-PF beyond the patient sample in this study is uncertain.
Missing from the sample were representative males, premen-
opausal female, and glucocorticoid-induced osteoporosis pa-
tients. Further validation work would be required in order to
confirm that the psychometric measurement properties report-
ed in this study are maintained in these other osteoporosis
patient populations. Finally, the impact of comorbidities on
OPAQ-PF scores is not fully understood and warrants further
investigation. Many participants reported comorbid conditions,
which is a common scenario in osteoporosis. It is known that
for some comorbid conditions it can be very difficult for the
patient to attribute the consequences of these in their OPAQ-PF
responses to their osteoporosis [20]. To overcome this, when
using the OPAQ-PF to evaluate treatment benefit, analyses
could be adjusted for presence of musculoskeletal or other
comorbidities (based on clinical examination or self-report).
Conclusions
The OPAQ-PF is a new PRO instrument uniquely tailored to
the assessment of the daily activities of physical function in
osteoporosis patients. This study demonstrated the strong
psychometric measurement properties of the OPAQ-PF by
providing evidence to support the conceptual framework,
reliability, validity, and sensitivity to change in a combined
recent fracture/no recent fracture osteoporosis sample through
a purpose-designed psychometric validation study which
gathered data from patients recruited through clinical sites in
the USA. A minimum change score of 10 at an individual
patient level, and 20 at a group level, was identified as poten-
tially representing a meaningful change from a patient per-
spective. The OPAQ-PF has been developed to meet FDA
regulatory requirements for PRO instruments intended to be
used in a phase 3 registration trial to support a label claim. It is
a suitable PRO instrument for capturing change in daily
activities of physical function of osteoporosis patients who
have experienced a recent fracture and maintenance in daily
activities of physical function of osteoporosis patients who
have not experienced a recent fracture.
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